FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely, to therapy and can be used to treat the complications of diabetes, atherosclerosis, rheumatoid arthritis, osteoarthritis, neurodegenerative diseases, including Alzheimer's and Parkinson’s diseases, cataracts, diseases associated with aging, etc. Use of Sulfasalazine Formula I as an inhibitor of the formation of glycation end products has been proposed.
.
EFFECT: use of the invention makes it possible to inhibit the end products of glycation with efficiency exceeding that of aminoguanidine.
1 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF NITRO-DERIVATIVE PHENOL-SULPHONIC ACIDS AS INHIBITORS OF FINAL GLYCATION PRODUCTS FORMATION | 2016 |
|
RU2628605C1 |
| INHIBITORS OF FORMATION OF GLYCATION END PRODUCTS BASED ON AZO-DERIVATIVE PHENYLSULPHONIC ACIDS | 2016 |
|
RU2634594C1 |
| USE OF HETEROCYCLIC HYDRAZONES AS AGENTS HAVING ANTIGLYCATING ACTIVITY | 2016 |
|
RU2658819C2 |
| SODIUM SALT OF DIETHYL ETHER OF 4-OXO-1,4-DIHYDROPYRAZOLO[5,1-C]-1,2,4-TRIAZINE-3,8-DICARBOXYLIC ACID MONOHYDRATE | 2015 |
|
RU2612300C1 |
| 3-GUANIDINOAZOLO[1,2,4,5]TETRAZINES HAVING ANTIGLYCATING ACTIVITY AND A PROCESS FOR THEIR PREPARATION | 2017 |
|
RU2668971C1 |
| SODIUM SALT OF 3-NITRO-4-OXO-1,4-DIHYDROPYRAZOLO[5,1-c]-1,2,4-TRIAZINE-8-CARBOXYLIC ACID, DIHYDRATE | 2016 |
|
RU2641107C1 |
| 2-(5-NITRONYLFURAN-2-YL)-5-METHYL-6-NITRO-1,2,4-TRIAZOLO[1,5-A]PYRIMIDIN-7(4N)-ONE AND SALTS THEREOF | 2018 |
|
RU2716715C2 |
| BIS[1,2,4]TRIAZOLO[4,3-b:3',4'-f][1,2,4,5]TETRAZINES WITH ANTI-GLYCATING, ANTI-GLYCOXIDATION AND ANTIPLATELET ACTIVITY | 2020 |
|
RU2755897C1 |
| PHARMACEUTICAL COMPOSITION OF ANTIGLYCATING ACTIVITY IN SOLID DOSAGE FORM IN FORM OF CAPSULES AND METHOD FOR PREPARATION THEREOF | 2019 |
|
RU2738804C1 |
| GENE-CELL VESICULAR THERAPEUTIC DRUG AND METHOD FOR MULTIPLE SCLEROSIS THERAPY BY TRANSPLANTATION OF A GENE-CELL VESICULAR THERAPEUTIC DRUG | 2021 |
|
RU2762855C1 |
